Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
CA 2378866 C · Owner: Merck Patent Gmbh · Inventors: Wesolowski, John S. Jr.; Lo, Kin Ming; Gillies, Stephen D.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Disclosed herein are methods and compositions for enhancing the immunogenicity of a preselected protein or peptide antigen in a mammal. Immunogenicity is enhanced by fusing the preselected antigen to an immunoglobulin heavy chain constant region to produce an Fc-antigen fusion protein. The Fc-antigen fusion proteins bind Fc receptors on the surface of antigen presenting cells thereby , targeting the antigen to the antigen presenting cells in the mammal. In addition, disclosed is a family of adjuvants for example, an Fc-adjuvant , fusion protein for use in combination with the Fc-antigen fusion proteins to enhance or modulate a particular immune response against the preselected …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed July 21, 2000 and granted June 7, 2011. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended July 21, 2020.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by July 21, 2022.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.